SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-066051
Filing Date
2022-03-04
Accepted
2022-03-04 16:02:00
Documents
13
Period of Report
2022-03-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d253295d8k.htm   iXBRL 8-K 26566
2 EX-10.1 d253295dex101.htm EX-10.1 221396
  Complete submission text file 0001193125-22-066051.txt   431783

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20220301.xsd EX-101.SCH 2865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20220301_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20220301_pre.xml EX-101.PRE 11713
7 EXTRACTED XBRL INSTANCE DOCUMENT d253295d8k_htm.xml XML 3480
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 22713976
SIC: 2834 Pharmaceutical Preparations